Supreme Court Turns Away CareDx Appeal in Natera Ad Dispute
The U.S. Supreme Court declined to hear CareDx's appeal in its false-advertising clash with Natera, leaving a lower court ruling in place.
The U.S. Supreme Court has rejected CareDx's petition to review a false-advertising dispute with rival diagnostics company Natera, Inc., letting stand the outcome reached by a lower federal court. The high court's refusal to take up the case marks a significant procedural setback for CareDx, which had sought a fresh look at claims tied to how Natera marketed its transplant-monitoring tests.
The case centers on competing diagnostics firms operating in the organ-transplant surveillance space, where both companies offer cell-free DNA tests designed to detect early signs of organ rejection in transplant recipients. False-advertising litigation in this niche but high-stakes medical market reflects the intense commercial rivalry over physician adoption and insurance reimbursement.
Read more Why U.S. Markets Continue to Defy 'Sell America' Predictions →
By declining the appeal without comment — the Court's standard practice when it turns away most petitions — the justices allowed the existing judgment to remain the final word, a result that broadly favors Natera's legal position heading into any remaining proceedings. CareDx now faces limited options for further federal judicial relief on the issues raised in its petition.
The outcome could have downstream implications for how diagnostics companies craft promotional claims around clinical studies, particularly in specialty markets where scientific nuance and marketing language frequently collide in court. Investors in both NTRA and CareDx were watching the docket closely given the potential liability and competitive ramifications a Supreme Court intervention might have triggered.
Continue reading at Yahoo Finance.
